REGULATORY
PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
The Pharmaceuticals and Medical Devices Agency (PMDA) will continue efforts to enhance Japan’s drug discovery capabilities in 2026, Chief Executive Yasuhiro Fujiwara says, pledging greater support for orphan and pediatric drug development in a bid to address drug losses. Speaking…
To read the full story
Related Article
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





